Sid Martin Biotech Alum DiaCarta's Biomarker Algorithm Predicts Response and Outcome of Chemotherapy (PR Newswire)

Sid Martin Biotech Alum DiaCarta’s Biomarker Algorithm Predicts Response and Outcome of Chemotherapy

UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company with proprietary technologies for the development of novel liquid biopsy oncology tests, announced the publication of a study in Nature Scientific Reports that demonstrates the company’s cfDNA biomarker algorithm could function as a prognostic biomarker and efficacy predictor for non-small cell lung cancer (NSCLC) patients.

The QuantiDNA™ cfDNA test is used to quantify the total amount of cfDNA directly from a plasma sample while the patient is undergoing cancer therapy. The test is highly accurate because it uses DiaCarta’s highly sensitive SuperbDNA™ technology, an extremely reliable and signal-specific amplification platform that allows quantitative detection of specific nucleic acid sequences directly from the source. Previously, the same test, known as RadTox™ test when used for radiotherapy toxicity measurement, was also used to demonstrate the cfDNA algorithm of the pre- and post-radiotherapy patient samples is a potential biomarker for radiotherapy safety measurement.

Read more about Sid Martin Biotech Alum DiaCarta’s Biomarker Algorithm Predicts Response and Outcome of Chemotherapy.
X